Assessing, preventing, and treating venous thromboembolism: Evidence-based approaches

American Journal of Health-System Pharmacy

Volumn 64, Issue 11 SUPPL., 2007, Pages

  Nutescu, Edith A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

American College of Chest Physicians; Anticoagulants; Critical illness; Dosage; Fondaparinux; Heparins; Kidney failure; Protocols; Risk management; Surgery; Thromboembolism; Warfarin; Weight

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; ENOXAPARIN; ESTROGEN; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; TINZAPARIN; WARFARIN;

BLEEDING; CLINICAL RESEARCH; CLINICAL TRIAL; COMPRESSION THERAPY; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG METABOLISM; EVIDENCE BASED MEDICINE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MORTALITY; PATIENT CARE; PATIENT SELECTION; POSTTHROMBOSIS SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; SURGICAL PATIENT; THROMBECTOMY; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

EID: 34249789594     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070108     Document Type: Conference Paper

References (46)

1. Lethen H, Flachskampf FA, Schneider R et al. Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack. Am J Cardiol. 1997; 80:1066-9.
2. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest. 1995; 108:978-81.
3. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med. 1989; 82:203-5.
4. Prandoni P, Villalta S, Bagatella P et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997; 82:423-8.
5. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 suppl):338S-400S.
6. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA. 1995; 274:335.
7. Samama MM, Cohen AT, Darmon JY et al. comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999; 341:793-800.
8. Anon. Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group. BMJ. 1992; 305:567-8.
9. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003; 107(23 suppl 1):I9-16.
10. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005; 51:70-8.
11. Lutz L, Haas S, Hach-Wunderle V et al. Venous thromboembolism in internal medicine: risk assessment and pharmaceutical prophylaxis: publication for the specialist platform. Med Welt. 2002; 53:231-4.
12. Cohen AT, Davidson BL, Gallus AS et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006; 332:325-9.
13. Arixtra package insert. Research Triangle Park, NC: GlaxoSmithKline; October 2005.
14. Mismetti P, Laporte-Simitsidis S, Tardy B et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 2000; 83:14-9.
15. Leizorovicz A, Cohen AT, Turpie AG et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004; 110:874-9.
16. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005; 106:2710-5.
17. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995; 332:1330-5.
18. Leyvraz PF, Bachmann F, Hoek J et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ. 1991; 303:543-8.
19. Mahlfeld K, Franke J, Schaeper O et al. [Heparin-induced thrombocytopenia as a complication of postoperative prevention of thromboembolism with unfractionated heparin/low molecular weight heparin after hip and knee prosthesis implantation]. Unfallchirurg. 2002; 105:327-31.
20. Ganzer D, Gutezeit A, Mayer G. [Potential risks in drug prevention of thrombosis - low-molecular-weight heparin versus standard heparin]. Z Orthop Ihre Grenzgeb. 1999; 137:457-61.
21. Pouplard C, May MA, Iochmann S et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation. 1999; 99:2530-6.
22. Goldhaber SZ, Tapson VF, DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004; 93:259-62.
23. Monreal M, Kakkar AK, Caprini JA et al. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry. J Thromb Haemost. 2004; 2:1892-8.
24. Tapson VF, Decousus H, Bergmann JF et al. The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE): Venous Thromboembolism Prophylaxis Practices in Acutely Ill Medical Patients. Blood. 2004; 104:11.Abstract#1762.meeting.bloodjournal.org/cgi/content/abstract/104/11/1762? maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext= tapson&searchid=1&FIRSTINDEX=0&volume=104&issue= 11&resourcetype=HWCIT (accessed 2006 Dec 30).
25. Stinnett JM, Pendleton R, Skordos L et al. Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol. 2005; 78:167-72.
26. Kucher N, Koo S, Quiroz R et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005; 352:969-77.
27. Büller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 suppl):401S-428S.
28. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349:146-53.
29. Merli G, Spiro TE, Olsson CG et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 2001; 134:191-202.
30. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002; 162:1729-35.
31. Dolovich LR, Ginsberg JS, Douketis JD et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000; 160:181-8.
32. Büller HR, Davidson BL, Decousus H et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004; 140:867-73.
33. Büller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003; 349:1695-702.
34. Fragmin package insert. New York, NY: Pfizer Inc; October 2006.
35. Lovenox package insert. Bridgewater, NJ: Aventis Pharmaceuticals Inc; November 2005.
36. Innohep package insert. Boulder, CO: Pharmion Corporation; November 2006.
37. Stobe J, Siegemund A, Achenbach H et al. Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. Int J Clin Pharmacol Ther. 2006; 44:455-65.
38. Lim W, Dentali F, Eikelboom JW et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006; 144:673-84.
39. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg. 2003; 90:547-8.
40. Samama MM, Varhille C, Dareby L. Relation between weight, obesity, and frequency of deep venous thrombosis after enoxaparin in orthopedic surgery. Thomb Haemost. 1995; 73:977.
41. Kucher N, Leizorovicz A, Vaitkus PT et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med. 2005; 165:341-5.
42. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 suppl):188S-203S.
43. Macie C, Forbes L, Foster GA, et al. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest. 2004; 125:1616-21.
44. Spinler SA, Dobesh P. Dose capping enoxaparin is unjustified and denies patients with acute coronary syndromes a potentially effective treatment. Chest. 2005; 127:2288-9.
45. Sanderink GJ, Le Liboux A, Jariwala N et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002; 72:308-18.
46. Hainer JW, Barrett JS, Assaid CA et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost. 2002; 87:817-23.